Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Ugne BalaseviciuteLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0002-4256-4336
Júlia Huguet-PradellLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0003-1489-356X
Jordi Abril-FornagueraLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0002-5871-4052
Albert Gris-OliverLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0003-1802-9541
Alex RialdiMount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elisa Fernández-MartínezMount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0009-0008-4390-5615
Carla MontironiLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0002-1453-2193
Vanessa Del PozoGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, USA.
Peter HoughtonGreehey Children's Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, USA.
Laura ZanattoFacultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Catalonia, Spain.
Agavni MesropianLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0002-0604-4755
Ieva KeraiteMount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1974-9479
Swan ThungDepartment of Pathology, ISMMS, New York, NY, USA.
Carolina ArmengolChildhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain.ORCID 0000-0002-4690-4027
Pau Sancho-BruInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain.ORCID 0000-0001-5569-9259
Ernesto GuccioneMount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-7764-5307
Roser PinyolLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0002-0288-6314
Josep M LlovetLiver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.ORCID 0000-0003-0547-2667
Funding
Hepatic stellate cells in NASH fibrosis and HCCR01DK128289 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT L. FRIEDMAN · 2021 to 2026
$2.6M
Determinants of immunotherapy response in NASH-Hepatocellular carcinomaR01CA273932 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JOSEP M LLOVET · 2023 to 2026
$2.0M
Hepatic autophagy, progenitor cells and fibrosisR56DK056621 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FRIEDMAN, SCOTT L. · 2015 to 2015
$297k
AGAUR 2021-SGR-01186AGAUR 2021-SGR 01347Asociación Española del Estudio del Hígado (AEEH)Cancer Research UKCris Cancer Foundation BT4ChildLCEASL International Liver Foundation (EILF)European Association for the Study of the Liver (EASL)European Commission (Horizon Europe-Mission Cancer, THRIVE) 101136622FEDERFederazione Italiana Associazioni Genitori e Guariti Oncoematologia PediatricaFondation KickCancerFondazione per la Ricerca sul Cancro (AIRC)Formación de Profesorado Universitario (FPU) FPU21/03361Foundation Kriibskrank KannerFundació de Recerca Clínic Barcelona-IDIBAPSFundación Científica de la Asociación Española Contra el Cáncer (FAECC)Fundació Universitària Agustí Pedro i PonsGeneralitat de Catalunya with a FI-SDUR Fellowship 2021 FISDU 00338HUNTER C9380/A26813Imagine for Margo"la Caixa" Foundation LCF/PR/SP23/52950009MICIU/AEIMontcelimar FoundationNCI NIH HHS R01 CA273932NIDDK NIH HHS R01 DK128289NIDDK NIH HHS R56 DK056621NIH HHS 1K99CA273538-01NIH HHS R01-CA273932-01NIH HHS R01DK128289NIH HHS R01DK56621PFISScientific Foundation of the Spanish Association Against Cancer IGTP-AECC_2022-042/PRYCO223102ARMESocietat Catalana de DigestologiaThe Asociación Española Contra el Cáncer EPAEC246711CLINThe Asociación Española Contra el Cáncer PRYGN223117LLOVThe Asociación Española Contra el Cáncer RETOS245779LLOVThe Samuel Waxman Cancer Research FoundationThe Spanish National Health Institute (MICINN) PID2022-139365OB-I00University of BarcelonaWorldwide Cancer Research 23-0356
6 · The paper itself
Abstract
Hepatoblastoma (HB), the most frequent pediatric liver cancer (2.16 cases/million), has surgery and perioperative chemotherapy as primary treatment, with severe lifelong side effects. This study evaluates the efficacy of the Wnt/CTNNB1 inhibitor WNTinib as a potential HB treatment, since CTNNB1 mutations occur in 70-90% of HBs. WNTinib's efficacy was assessed in three animal models (n = 48): (a) patient-derived xenograft (PDX) HB tumors (n = 5 CTNNB1-mutant, n = 1 CTNNB1 wild-type) implanted in NSG mice; (b) PDX-derived TT001- and (c) HepG2-HB cells subcutaneously implanted in Fox1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib. · full record | OpenQuestion